# OnCo record repotrectinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/repotrectinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "repotrectinib" ;
  schema:name "Repotrectinib"@en ;
  schema:description "A ROS1 and NTRK pill that also works after other ROS1 drugs fail, with dizziness as its signature side effect."@en ;
  schema:url <https://onco.cc/drugs/repotrectinib/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Repotrectinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q123499554> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Repotrectinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (ROS1 / NTRK)" ;
  schema:alternateName "Augtyro" ;
  onco:approval "US 2023: ROS1+ locally advanced or metastatic NSCLC", "US 2024: NTRK-fusion solid tumours (tumour-agnostic)", "EU 2025: ROS1+ NSCLC; NTRK+ solid tumours; 13 Jan 2025 (conditional)" ;
  onco:acceleratedApproval "US 2024-06-13: Treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic where surgical resection is likely results in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy" ;
  onco:related <https://onco.cc/biomarkers/ros1-fusion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/ros1-positive-nsclc/>, <https://onco.cc/cancers/ntrk-fusion-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/ros1/>, <https://onco.cc/targets/ntrk/> ;
  onco:drugs <https://onco.cc/drugs/zidesamtinib/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:trials <https://onco.cc/trials/nct04094610/>, <https://onco.cc/trials/nct03093116/>, <https://onco.cc/trials/nct06140836/> .